3D Cell Culture Market - Segmented By Product Type (Scaffold-Based Platforms, Bioreactors, Gels, Microchips, and Services), By Application (Stem Cell Research, Cancer Research, Regenerative Medicine, and Drug Discovery), By End-User (Contract Research Laboratories, Biotechnology & Pharmaceutical Companies, and Academic Institutes), and By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026

Description

The global 3D Cell Culture market, which will accrue proceeds worth 2,232.60 (USD Million) by 2026, is set to record the CAGR of nearly 16.1% over the period from 2020 to 2026. The report offers assessment and analysis of the 3D Cell Culture market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, sales estimates, opportunities, evolving trends, and industry-validated data. The report offers historical data from 2017 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Million).

Introduction

3D cell culture tools are used in drug discovery process, tissue engineering, stem cell study, cell-based sensors, cancer cell biology, and stem cell study. As per NCBI, 3D cell culture systems have proved to be most effective sensing tools in cell based sensors as they provide biologically accurate information as well as predictive data for in vivo clinical trials. Furthermore, 3D cell culture has the ability to bring a paradigm shift in toxicology research activities. For instance, 3D cell culture models help in effectively studying the impact of toxicants on liver, testis, lungs, kidneys, heart, skins, gastrointestinal tract, and brain. NIH researchers have reported that 3D cell culture prototypes can also prove beneficial in comprehensive carcinogenesis study.

Market Growth Dynamics

The growth of 3D cell culture industry over estimated timespan is owing to escalating focus on personalized medicine along with increasing cases of chronic disorders across the globe. Rising demand for organ transplants and contribution of 3D cell culture models towards new drug development for treating cancer will embellish the market trends. Apart from this, massive use of 3D cell culture techniques in drug screening and efforts made by researchers for developing standard protocols in drug screening will chart a profitable growth graph for the market over the coming years.

Furthermore, 3D cell culture based biosensors create 3D cell structures as the latter can exhibit in vivo distribution of nutrients, signaling drugs, metabolites, and oxygen. Additionally, with the onset of new techniques like lab-on-a-chip technique, the market for 3D cell culture is likely to gain traction over the ensuing years. Large-scale funding for research & development activities pertaining to 3D cellular models will further steer the business growth over the estimated timespan.

North America To Contribute Major Market Revenue Over Forecast Timespan  

The growth of the market in the region over the forecast timespan is due to huge healthcare funding in biotech & pharmaceutical research in the countries like the U.S. and Canada. In addition to this, massive need for drug discovery with surge in the cases of chronic ailments in the region will spur the market expansion in North America over the estimated timespan.

Key participants profiled in the report are Synthecon, REPROCELL Incorporated, Corning Incorporated, Advanced BioMatrix, Thermo Fisher Scientific, Lonza AG, QGel SA, SynVivo, Hµrel Corporation, Merck KGaA, TissUse, InSphero, CN Bio, 3D Biotek, MIMETAS, Hamilton Company, Emulate, Greiner Bio-One International, and PromoCell.

The global 3D cell culture market is segmented as follows:

By product type:

• Scaffold-Based Platforms
  • Macro-Porous Scaffolds
  • Scaffold-Free Platforms
  • Micro-Porous Scaffolds
  • Nano-Porous Scaffolds
  • Solid Scaffolds
• Bioreactors
• Gels
• Microchips
• Services

By application:

• Cancer Research
• Regenerative Medicine
• Stem Cell Research
• Drug Discovery

By end-user:

• Contract Research Laboratories
• Biotechnology & Pharmaceutical Companies
• Academic Institutes

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table Of Content

• Chapter 1. Preface
  • 1.1. Report Description and Scope
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology
• Chapter 2. Executive Summary
  • 2.1. 3D Cell Culture Market, 2016–2026(USD Million)
  • 2.2. 3D Cell Culture Market: Snapshot
• Chapter 3. Global 3D Cell Culture Market– Industry Analysis
  • 3.1. 3D Cell Culture Market: Market Dynamics
  • 3.2. Market Drivers
    • 3.2.1. Rising demand for organ transplants and contribution of 3D cell culture models towards new drug development for treating cancer will embellish the market trends.
    • 3.2.2. Massive use of 3D cell culture techniques in drug screening and efforts made by researchers for developing standard protoculs in drug screening will chart a profitable growth graph for the market over the coming years.
  • 3.3. Market Attractiveness Analysis
    • 3.3.1. Market attractiveness analysis By Product Type
    • 3.3.2. Market attractiveness analysis By Application
    • 3.3.3. Market attractiveness analysis By End-User
• Chapter 4. Global 3D Cell Culture Market– Competitive Landscape
  • 4.1. Company market share analysis
    • 4.1.1. Global 3D Cell Culture Market: company market share, 2019
  • 4.2. Strategic development
    • 4.2.1. Acquisitions & mergers
    • 4.2.2. New Product Type launches
    • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
    • 4.2.4. Research and development and Regional expansion
  • 4.3. Price trend analysis
• Chapter 5. Global 3D Cell Culture Market–Product Type Analysis
  • 5.1. Global 3D Cell Culture Market overview: By Product Type
    • 5.1.1. Global 3D Cell Culture Market share, By Product Type,2019 and 2026
  • 5.2. SCAFFulD-BASED PLATFORMS
    • 5.2.1. Global 3D Cell Culture Market by SCAFFulD-BASED PLATFORMS, 2016–2026(USD Million)
  • 5.3. BIOREACTORS
    • 5.3.1. Global 3D Cell Culture Market by BIOREACTORS, 2016–2026(USD Million)
  • 5.4. GELS
    • 5.4.1. Global 3D Cell Culture Market by GELS, 2016–2026(USD Million)
  • 5.5. Microchips
    • 5.5.1. Global 3D Cell Culture Market by Microchips, 2016–2026(USD Million)
  • 5.6. Services
    • 5.6.1. Global 3D Cell Culture Market by Services, 2016–2026(USD Million)
• Chapter 6. Global Flame Detector Market– Application Analysis
  • 6.1. Global 3D Cell Culture Market overview: By Application
    • 6.1.1. Global 3D Cell Culture Market share, By Application, 2019 and 2026
  • 6.2. Stem Cell Research
    • 6.2.1. Global 3D Cell Culture Market By Stem Cell Research , 2016–2026(USD Million)
  • 6.3. CANCER RESEARCH
    • 6.3.1. Global 3D Cell Culture Market By CANCER RESEARCH, 2016–2026(USD Million)
  • 6.4. Regenerative Medicine
    • 6.4.1. Global 3D Cell Culture Market By Regenerative Medicine, 2016–2026(USD Million)
  • 6.5. Drug Discovery
    • 6.5.1. Global 3D Cell Culture Market By Drug Discovery, 2016–2026(USD Million)
• Chapter 7. Global Flame Detector Market– End-User Analysis
  • 7.1. Global 3D Cell Culture Market overview: By End-User
    • 7.1.1. Global 3D Cell Culture Market share, By End-User , 2019 and 2026
  • 7.2. Contract Research Organization (CRO)
    • 7.2.1. Global 3D Cell Culture Market By Contract Research Organization (CRO), 2016–2026(USD Million)
  • 7.3. Biotechnulogy & Pharmaceutical Companies
    • 7.3.1. Global 3D Cell Culture Market By Biotechnulogy & Pharmaceutical Companies, 2016–2026(USD Million)
  • 7.4. Academic Institutes
    • 7.4.1. Global 3D Cell Culture Market By Academic Institutes, 2016–2026(USD Million)
• Chapter 8. Company Profiles
  • 8.1. Corning Incorporated
    • 8.1.1. Overview
    • 8.1.2. Financials
    • 8.1.3. Product Portfolio
    • 8.1.4. Business Strategy
    • 8.1.5. Recent Developments
  • 8.2. Thermo Fisher Scientific
    • 8.2.1. Overview
    • 8.2.2. Financials
    • 8.2.3. Product Portfolio
    • 8.2.4. Business Strategy
    • 8.2.5. Recent Developments
  • 8.3. Lonza AG
    • 8.3.1. Overview
    • 8.3.2. Financials
    • 8.3.3. Product Portfolio
    • 8.3.4. Business Strategy
    • 8.3.5. Recent Developments
  • 8.4. Merck KgaA
    • 8.4.1. Overview
    • 8.4.2. Financials
    • 8.4.3. Product Portfolio
    • 8.4.4. Business Strategy
    • 8.4.5. Recent Development
  • 8.5. TissUse
    • 8.5.1. Overview
    • 8.5.2. Financials
    • 8.5.3. Product Portfolio
    • 8.5.4. Business Strategy
    • 8.5.5. Recent Development
  • 8.6. REPROCELL Incorporated
    • 8.6.1. Overview
    • 8.6.2. Financials
    • 8.6.3. Product Portfolio
    • 8.6.4. Business Strategy
    • 8.6.5. Recent Development
  • 8.7. Synthecon
    • 8.7.1. Overview
    • 8.7.2. Financials
    • 8.7.3. Product Portfolio
    • 8.7.4. Business Strategy
    • 8.7.5. Recent Development
  • 8.8. InSphero
    • 8.8.1. Overview
    • 8.8.2. Financials
    • 8.8.3. Product Portfolio
    • 8.8.4. Business Strategy
    • 8.8.5. Recent Development
  • 8.9. CN Bio
    • 8.9.1. Overview
    • 8.9.2. Financials
    • 8.9.3. Product Portfolio
    • 8.9.4. Business Strategy
    • 8.9.5. Recent Development
  • 8.10. 3D Biotek
    • 8.10.1. Overview
    • 8.10.2. Financials
    • 8.10.3. Product Portfolio
    • 8.10.4. Business Strategy
    • 8.10.5. Recent Development
  • 8.11. MIMETAS
    • 8.11.1. Overview
    • 8.11.2. Financials
    • 8.11.3. Product Portfolio
    • 8.11.4. Business Strategy
    • 8.11.5. Recent Development
  • 8.12. Hamilton Company
    • 8.12.1. Overview
    • 8.12.2. Financials
    • 8.12.3. Product Portfolio
    • 8.12.4. Business Strategy
    • 8.12.5. Recent Development
  • 8.13. Hµrel Corporation
    • 8.13.1. Overview
    • 8.13.2. Financials
    • 8.13.3. Product Portfolio
    • 8.13.4. Business Strategy
    • 8.13.5. Recent Development
  • 8.14. Emulate
    • 8.14.1. Overview
    • 8.14.2. Financials
    • 8.14.3. Product Portfolio
    • 8.14.4. Business Strategy
    • 8.14.5. Recent Development
  • 8.15. SynVivo
    • 8.15.1. Overview
    • 8.15.2. Financials
    • 8.15.3. Product Portfolio
    • 8.15.4. Business Strategy
    • 8.15.5. Recent Development
  • 8.16. QGel SA
    • 8.16.1. Overview
    • 8.16.2. Financials
    • 8.16.3. Product Portfolio
    • 8.16.4. Business Strategy
    • 8.16.5. Recent Development
  • 8.17. Greiner Bio-One International
    • 8.17.1. Overview
    • 8.17.2. Financials
    • 8.17.3. Product Portfolio
    • 8.17.4. Business Strategy
    • 8.17.5. Recent Development
  • 8.18. Advanced BioMatrix
    • 8.18.1. Overview
    • 8.18.2. Financials
    • 8.18.3. Product Portfolio
    • 8.18.4. Business Strategy
    • 8.18.5. Recent Development
  • 8.19. PromoCell
    • 8.19.1. Overview
    • 8.19.2. Financials
    • 8.19.3. Product Portfolio
    • 8.19.4. Business Strategy
    • 8.19.5. Recent Development

Methodology